DLX6 and cancer: The pooled HR indicated that higher DLX6-AS1 expression was related to worse survival (high DLX6-AS1 expression group versus low DLX6-AS1 expression; pooled HR = 2.30, 95% CI: 1.70–3.09, P<0.01, Figure 3), which demonstrated that DLX6-AS1 was a risk factor for the prognosis of cancer patients.